ArticlePLoS neglected tropical diseases2024
A global chromoblastomycosis strategy and development of the global chromoblastomycosis working group.
Article in PLoS neglected tropical diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Molecular Evidence of Autochthonous Environmental Acquisition ofOpen forum infectious diseases · 2026Article
- Establishment of epidemiological cutoff values againstJournal of clinical microbiology · 2026Article
- Forest-river interfaces shape lobomycosis risk in the Amazon Basin.PLoS neglected tropical diseases · 2026Article
- Contribution of fungal diseases to the U.S. chronic disease burden.Clinical microbiology reviews · 2026Review
- Integrated action for skin NTDs: Deconstructing transmission, addressing knowledge gaps, and championing one health strategies.Nature communications · 2026Review
- Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies.Current fungal infection reports · 2026Article
- Article
- Chromoblastomycosis caused byIDCases · 2026Article
- The Current Landscape of Repurposed Drugs for Fungal Neglected Tropical Diseases.Current fungal infection reports · 2025Article
- Chromoblastomycosis and phaeohyphomycotic abscess-associated hospitalizations, United States, 2016-2021.PLoS neglected tropical diseases · 2025Article
- Chromoblastomycosis in Peru: a retrospective review of 13 cases.BMC infectious diseases · 2025Article
- Bridging gaps in the elimination of deep mycoses: a comparative analysis of mycetoma and chromoblastomycosis control strategies in Rwanda and China.Tropical medicine and health · 2025Review
- Chromoblastomycosis, Phaeohyphomycotic Abscess, and Sporotrichosis Among American Indian/Alaska Natives, Indian Health Service, 2016-2022.The American journal of tropical medicine and hygiene · 2025Article
- Cerebral Chromoblastomycosis: A Unique Presentation of Dematiaceous Fungal Infection in an Immunocompromised Patient.Annals of Indian Academy of Neurology · 2025Article
- Chromoblastomycosis: a case series from Sumba, eastern Indonesia.Clinical and experimental dermatology · 2025Article
- Establishment of epidemiological cutoff values forJournal of clinical microbiology · 2025Article
- Quality of Life, Disability, and Fungal Neglected Tropical Diseases.Current fungal infection reports · 2025Article
- South-East Asia regional neglected tropical disease framework: improving control of mycetoma, chromoblastomycosis, and sporotrichosis.The Lancet regional health. Southeast Asia · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Chromoblastomycosis, an implantation mycosis, is a neglected tropical disease that causes decreased quality of life, stigma, and disability. The global burden of disease is unknown and data on disease epidemiology and outcomes are severely limited by a lack of access to needed diagnostic tools and therapeutics. The World Health Organization outlined targets for chromoblastomycosis in the Road Map for Neglected Tropical Diseases 2021-2030, but little progress has been made in initiating and implementing an effective control program globally. This lack of guiding policy and progress led to the recent formation of a Global Chromoblastomycosis Working Group which has developed a global chromoblastomycosis strategy. We describe this strategy, which outlines specific steps needed to improve technical progress, strategy and service delivery, and enablers. Clinicians, researchers, public and government officials, patients, and policy makers can align their time, expertise, and resources to improve the lives of communities affected by chromoblastomycosis through this strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.